Durability of mRNA-1273 protection against symptomatic COVID-19 examined
Jun 13, 2022
Among those receiving two doses of the Moderna vaccine, peak vaccine efficacy against symptomatic COVID-19 was estimated to be 94.1% at 120 days after the first dose.
FDA approval of new COVID-19 boosters could come by Friday
Sep 07, 2023
The new booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
Just 7 percent of US adults have gotten updated COVID-19 vaccine
Oct 27, 2023
The new shot targets a highly contagious variant that is in wide circulation nationwide.
FDA panel to weigh improved booster shots from Moderna, Pfizer
Jun 27, 2022
Both Pfizer and Moderna have been testing updated booster shots that target the omicron variant.
COVID-19 vaccination bests natural immunity for cutting death, hospitalizations
Dec 28, 2022
Natural immunity, however, was tied to a lower incidence of new infection.
Electronic reminders boost flu vaccine uptake in older adults
Mar 22, 2023
Letters highlighting the potential cardiovascular benefits of influenza vaccination were found to be particularly effective.
Two top officials in FDA vaccine review office to retire
Sep 01, 2021
The retirements come as the agency mulls decisions about COVID-19 vaccine approvals, authorizations for younger children, and booster shots.
No increase in Guillain-Barré syndrome seen after COVID-19 vaccination in adults
Oct 17, 2022
The reporting rate of Guillain-Barré syndrome was higher compared with other vaccinations, but the rate was within the incidence range for the general population.
FDA approves Pfizer RSV vaccine for older adults
Jun 01, 2023
The CDC is expected to meet later in the month to adopt vaccine recommendations for older Americans.
Serious adverse effects from COVID-19 vaccines reported rarely
Jan 05, 2022
Full vaccination dose, younger age, female sex and previously having had COVID-19 were linked to greater odds of adverse effects.